Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› SCLC, Extensive Stage
Clinical trial register · China

SCLC, Extensive Stage Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 5 Shanghai 3 Luoyang 2 Tianjin 2 Hangzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5 Shanghai3 Luoyang2 Tianjin2 Hangzhou1
All 18 locations
Target enrolment
to

SCLC, Extensive Stage trials in China

15 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer
NCT07909863Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2026-11-15
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
442
Guangzhou, Shenyang
2026-08-18
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
9
Beijing
2026-02-20
Recruiting
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
NCT07480213Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
25
Tianjin
2026-02-01
Recruiting
Shanghai AB PharmaTech Ltd.
Phase 2
110
Luoyang, Nanyang, Nanchang, Liaocheng, Shanghai, Taiyuan, Neijiang
2025-12-30
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
20
Beijing, Chongqing
2025-10-31
Recruiting
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
NCT07508852SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer
Peking University First Hospital
Phase 1/2
30
Beijing
2025-10-22
Recruiting
Tang-Du Hospital
Phase 2
32
Xi'an
2025-08-25
Not yet open
Henan Cancer Hospital
Phase 2
250
Luoyang, Xinxiang, Zhengzhou
2025-01-15
Recruiting
Peking University Cancer Hospital & Institute
Phase 2
60
Beijing
2025-01-07
Active, closed
Sichuan University
Phase 1/2
57
Chengdu
2024-05-16
Recruiting
Fudan University
Phase 1/2
56
Shanghai
2024-01-15
Recruiting
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
Phase 1/2
27
Hangzhou, Shanghai
2023-07-24
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 November 2026. https://priyalifescience.com/clinical-trials-china/condition/sclc-extensive-stage

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies listing the condition SCLC, Extensive Stage.

How many SCLC, Extensive Stage trials are recruiting in China?

12 of the 15 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (SCLC, Extensive Stage), 15 studies
PhaseStudiesRecruitingShare
Phase 27546.7%
Phase 1/25433.3%
Phase 12213.3%
Phase 3116.7%

Most active sponsors

Lead sponsors with the most studies (SCLC, Extensive Stage)
Lead sponsorStudiesRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences22
Peking University Cancer Hospital & Institute22
Tianjin Medical University Cancer Institute and Hospital21
Beijing Biotech11
Fudan University11
Henan Cancer Hospital10
MediLink Therapeutics (Suzhou) Co., Ltd.11
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.11
Peking University First Hospital11
Shanghai AB PharmaTech Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.